1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-018-30070-z
DC FieldValue
dc.titleConservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer
dc.contributor.authorTan, H.L
dc.contributor.authorYong, C
dc.contributor.authorTan, B.Z
dc.contributor.authorFong, W.J
dc.contributor.authorPadmanabhan, J
dc.contributor.authorChin, A
dc.contributor.authorDing, V
dc.contributor.authorLau, A
dc.contributor.authorZheng, L
dc.contributor.authorBi, X
dc.contributor.authorYang, Y
dc.contributor.authorChoo, A
dc.date.accessioned2020-10-20T03:25:38Z
dc.date.available2020-10-20T03:25:38Z
dc.date.issued2018
dc.identifier.citationTan, H.L, Yong, C, Tan, B.Z, Fong, W.J, Padmanabhan, J, Chin, A, Ding, V, Lau, A, Zheng, L, Bi, X, Yang, Y, Choo, A (2018). Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer. Scientific Reports 8 (1) : 11608. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-018-30070-z
dc.identifier.issn20452322
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/177811
dc.description.abstractMonoclonal antibodies (mAbs) are used as targeted therapies against cancers. These mAbs kill cancer cells via various mechanisms of actions. In this study, human embryonic stem cells (hESCs) was used as the immunogen to generate a panel of antibodies. From this panel of mAbs, A19 was found to bind both hESC and various cancer cell lines. The antigen target of A19 was identified as Erbb-2 and glycan analysis showed that A19 binds to a N-glycan epitope on the antigen. A19 was elucidated to internalize into cancer cells following binding to Erbb-2 and hence developed as an antibody-drug conjugate (ADC). Using ADC as the mechanism of action, A19 was able to kill cancer cells in vitro and delayed the onset of tumour formation in mice xenograft model. When compared to Herceptin, A19 binds to different isoforms of Erbb-2 and does not compete with Herceptin for the same epitope. Hence, A19 has the potential to be developed as an alternative targeted therapeutic agent for cancers expressing Erbb-2. © 2018, The Author(s).
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectimmunological antineoplastic agent
dc.subjectmonoclonal antibody
dc.subjectoncofetal antigens
dc.subjecttumor antigen
dc.subjectanimal
dc.subjectBagg albino mouse
dc.subjectdrug screening
dc.subjectexperimental neoplasm
dc.subjectfemale
dc.subjecthuman
dc.subjecthuman embryonic stem cell
dc.subjectimmunology
dc.subjectnude mouse
dc.subjectpathology
dc.subjecttumor cell line
dc.subjectAnimals
dc.subjectAntibodies, Monoclonal, Murine-Derived
dc.subjectAntigens, Neoplasm
dc.subjectAntineoplastic Agents, Immunological
dc.subjectCell Line, Tumor
dc.subjectFemale
dc.subjectHuman Embryonic Stem Cells
dc.subjectHumans
dc.subjectMice, Inbred BALB C
dc.subjectMice, Nude
dc.subjectNeoplasms, Experimental
dc.subjectXenograft Model Antitumor Assays
dc.typeArticle
dc.contributor.departmentBIOMEDICAL ENGINEERING
dc.description.doi10.1038/s41598-018-30070-z
dc.description.sourcetitleScientific Reports
dc.description.volume8
dc.description.issue1
dc.description.page11608
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-018-30070-z.pdf1.4 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons